Location · Washington D.C., DC
Clinical trials in Washington D.C., DC
221 recruiting studies have a site in Washington D.C., and 73 of them accept healthy volunteers.
221 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
AstraZeneca
- Location
- Washington D.C., DC + 30 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
AstraZeneca
- Location
- Washington D.C., DC + 15 other US sites
- Eligibility basics
- Ages 12+
- Recruiting
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
Shockwave Medical, Inc.
- Location
- Washington D.C., DC + 66 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
AstraZeneca
- Location
- Washington D.C., DC + 18 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 2
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Immunovant Sciences GmbH
- Location
- Washington D.C., DC + 30 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
Ascendis Pharma A/S
- Location
- Washington D.C., DC + 21 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 3
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
UCB Biopharma SRL
- Location
- Washington D.C., DC + 41 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Washington D.C., DC + 27 other US sites
- Eligibility basics
- Ages 55–84
- RecruitingPhase 3
Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery
Octapharma
- Location
- Washington D.C., DC + 4 other US sites
- Eligibility basics
- Ages 12–80
- RecruitingPhase 2/Phase 3
Nectero EAST System Clinical Study
Nectero Medical, Inc.
- Location
- Washington D.C., DC + 35 other US sites
- Eligibility basics
- Ages 21–85
- RecruitingPhase 2
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Novartis Pharmaceuticals
- Location
- Washington D.C., DC + 22 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingPhase 1
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
Pfizer
- Location
- Washington D.C., DC + 10 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 3
A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
Neuren Pharmaceuticals Limited
- Location
- Washington D.C., DC + 16 other US sites
- Eligibility basics
- Ages 3–12
- RecruitingPhase 3
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
ViiV Healthcare
- Location
- Washington D.C., DC + 36 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
Novo Nordisk A/S
- Location
- Washington D.C., DC + 32 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
AstraZeneca
- Location
- Washington D.C., DC + 104 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
CorMedix Therapeutics
- Location
- Washington D.C., DC + 16 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
Janssen Research & Development, LLC
- Location
- Washington D.C., DC + 9 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Pfizer
- Location
- Washington D.C., DC + 69 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Pfizer
- Location
- Washington D.C., DC + 54 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 1
Study of GS-0415 and How It Works in People With HIV
Gilead Sciences
- Location
- Washington D.C., DC + 14 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
Sanofi
- Location
- Washington D.C., DC + 6 other US sites
- Eligibility basics
- Ages 1–18
- RecruitingPhase 3
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
Novartis Pharmaceuticals
- Location
- Washington D.C., DC + 39 other US sites
- Eligibility basics
- Ages 21–70
- RecruitingPhase 2/Phase 3
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
Corxel Pharmaceuticals
- Location
- Washington D.C., DC + 19 other US sites
- Eligibility basics
- Ages 18–90